Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

1 year ago

Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413 is a bi-specific antibody…

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories

1 year ago

VANCOUVER, Washington, Sept. 24, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab,…

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

1 year ago

An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going…

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

1 year ago

Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

1 year ago

Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within…

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

1 year ago

TRxADE Health, Inc. today announced that it changed its name and ticker symbol to “Scienture Holdings, Inc.” and “SCNX”, respectively,…

Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner

1 year ago

Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner Jack Springer, President and CEO of Nectero Medical (center)…

Spectral AI Achieves 25% Patient Enrollment at Emergency Departments for U.S. Burn Pivotal Study and Adds Two New Clinical Trial Sites

1 year ago

DALLAS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…

Starton Therapeutics’ Chief Executive Officer Chosen as 2024 Honoree by the Icla da Silva Foundation

1 year ago

PARAMUS, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming…